CELLTRION, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 191,500 KRW | -0.78% |
|
-0.73% | -4.96% |
| May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
| Apr. 24 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3,534B 2.62B | Sales 2025 * | 4,201B 3.11B | Capitalization | 39,491B 29.22B |
|---|---|---|---|---|---|
| Net income 2024 * | 552B 408M | Net income 2025 * | 1,126B 833M | EV / Sales 2024 * | 11.3 x |
| Net Debt 2024 * | 544B 403M | Net cash position 2025 * | 261B 193M | EV / Sales 2025 * | 9.34 x |
| P/E ratio 2024 * |
74.2
x | P/E ratio 2025 * |
36.1
x | Employees | 2,034 |
| Yield 2024 * |
0.23% | Yield 2025 * |
0.24% | Free-Float | 66.01% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.78% | ||
| 1 week | -0.73% | ||
| Current month | +1.32% | ||
| 1 month | +11.99% | ||
| 3 months | +5.10% | ||
| 6 months | +13.72% | ||
| Current year | -4.96% |
1 week
188 300.00
195 400.00
1 month
171 000.00197 000.00
Current year
169 700.00241 000.00
1 year
131 000.00241 000.00
3 years
131 000.00283 276.77
5 years
121 026.29372 915.00
10 years
27 751.54372 915.00
| Managers | Title | Age | Since |
|---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jae-Sik Lee
BRD | Director/Board Member | 66 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.14% | 2 M€ | -14.14% | ||
| 0.99% | 11 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 191,500 | -0.78% | 1,000,223 |
| 24-05-16 | 193,000 | +1.10% | 466,199 |
| 24-05-14 | 190,900 | +0.05% | 277,583 |
| 24-05-13 | 190,800 | -1.09% | 443,306 |
| 24-05-10 | 192,900 | +1.69% | 715,282 |
End-of-day quote Korea S.E., May 16, 2024
More quotes
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Calendar
2024-11-10
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
191,500
KRW
Average target price
232,471
KRW
Spread / Average Target
+21.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.96% | 29.18B | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +28.31% | 12.16B | |
| +24.73% | 12.17B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- A068270 Stock
